L Kadabur, D Koppaka, GB Kanakasetty, A Usha, LC Kuntegowdanahalli, L Dasappa, LA Jacob, SMC Babu, RA Haleshappa, A Abhishek, LK Rajeev
Indian Journal of Cancer 2017 54(1):228-230
Wide use and incorporation of newer diagnostic tools in the management of metastatic nonsmall cell lung cancer (NSCLC) has helped in achieving the goal of personalized treatment of this disease. With the wide use of polymerase chain reaction and fluorescence in situ hybridization increasing number of patients are being diagnosed with dual and complex mutations posing a new challenge in the management of patient with metastatic NSCLC. In this article, we would like to bring forth six such cases and the varied responses to the current available treatment in patients with complex and dual mutations. The appropriate management in these groups of patients is yet to be standardized.
from Cancer via ola Kala on Inoreader http://ift.tt/2i82prR
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου